Tau aggregation induces cell death in iPSC-derived neurons

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Abnormal tau protein accumulation in the brain is a hallmark of neurodegenerative diseases like Alzheimer's disease (AD).
• Tau pathology correlates with neuronal cell death and disease progression, making it a significant therapeutic target for AD.
• Existing models face challenges in rapidly screening tau-targeting therapeutics due to species-specific cellular responses.

Purpose of the Study:

• To establish a human cellular model for rapid screening of tau-targeting therapeutics.
• To investigate tau aggregation-dependent neuronal cell death in a human cell system.
• To validate the utility of the model for assessing neuroprotective compound efficacy.

Main Methods:

• Overexpression of tau protein in a human cellular platform.
• Induction of tau aggregation and subsequent neuronal cell death.
• Assessment of neuroprotective effects of known tau-targeting compounds.

Main Results:

• Successfully established a human cellular model exhibiting tau aggregation-dependent neuronal cell death within two weeks.
• Demonstrated the model's capacity to recapitulate key aspects of tau-induced neurodegeneration.
• Confirmed the neuroprotective efficacy of established tau-targeting compounds in the developed system.

Conclusions:

• The developed human cellular model effectively recapitulates tauopathy pathogenesis.
• This platform offers a valuable tool for accelerated drug discovery and screening in tauopathies.
• The model facilitates the identification of novel therapeutics for neurodegenerative diseases characterized by tau accumulation.